Key takeaways
- SNAP-8 (acetyl octapeptide-3) is argireline with two extra amino acids, made for skin creams aimed at expression lines.
- The headline wrinkle numbers come from the ingredient's maker, not from independent trials.
- Only two PubMed-indexed human studies include it, and both mixed it with other actives in microneedle patches.
- It is a cosmetic ingredient, not an approved drug, and it has never been studied as an injection.
SNAP-8 shows up in a lot of "Botox in a bottle" serums. The pitch is simple: a small peptide that quiets the nerve signals behind crow's feet and forehead lines, without a needle.
We went looking for the human data behind that pitch. There is some, but far less than the marketing suggests, and most of the useful evidence is actually about its shorter parent, argireline.
What SNAP-8 is and how it is supposed to work
SNAP-8 is an eight-amino-acid peptide (INCI name acetyl octapeptide-3). It is a lengthened version of argireline (acetyl hexapeptide-3, also listed as acetyl hexapeptide-8), the six-amino-acid peptide it was built from.
Both copy a short piece of SNAP-25, a protein nerve endings use to release signals to muscle. The idea is that the peptide competes for a spot in the SNARE complex, the machinery that releases those signals. In lab tests this slightly dampens signal release, which in theory relaxes the small muscles behind expression lines. It is far weaker than botulinum toxin, and how well it gets through skin is debated.
On MyPeps, SNAP-8 sits at evidence level 1 of 5: mostly lab work and manufacturer-run cosmetic tests, with very little independent, peer-reviewed human data. Its half-life in humans has not been characterized.
Where the argireline idea came from
The original argireline paper, from a Spanish university team working with the ingredient's developer, appeared in 2002 1. In lab models the hexapeptide interfered with SNARE complex formation and inhibited neurotransmitter release, though with much lower efficacy than botulinum toxin A. A cream containing 10% of the peptide reduced wrinkle depth by up to 30% in healthy women after 30 days 1.
The best-known independent test of argireline is a 2013 randomized, placebo-controlled study in 60 Chinese adults 2. People applied argireline or placebo around the eyes twice daily for 4 weeks. The argireline group had a 48.9% "total anti-wrinkle efficacy" on subjective grading, versus 0% for placebo, and skin-replica roughness measures fell in the argireline group but not the placebo group 2.
That is a real signal, but it is one short, small study of a different peptide. SNAP-8 is often described as a stronger version of argireline, yet we found no published head-to-head comparison in humans.
The SNAP-8 numbers you see online
The figure repeated across supplier pages is "up to 63% wrinkle reduction." A 2016 trade-magazine feature on the ingredient reports a 63% maximum wrinkle depth reduction after 28 days in women volunteers using a cream with 10% SNAP-8 3. That article does not say how many volunteers took part or whether there was a placebo group, and the data comes from the ingredient's manufacturer.
A "maximum" reduction is the best result in the group, not the average. Without a control group, sample size or peer review, it can't be compared with the argireline trial above.
The only peer-reviewed human studies that include it
A PubMed search for "acetyl octapeptide-3" returns two papers. Both tested microneedle patches, not plain creams, and both combined SNAP-8 with other active ingredients.
- A 12-week, single-center study tested hyaluronic acid microneedle patches containing acetyl octapeptide-3 alongside palmitoyl tripeptide-5, an arginine/lysine polypeptide, adenosine and seaweed extracts 4. The authors reported a 25.8% decrease in fine lines and wrinkles and no skin reactions. There was no placebo arm, and the authors were from the patch makers and the testing lab.
- A 2024 study in 24 healthy adults put a patch with acetyl octapeptide-3, a vitamin C derivative and a lipid signaling molecule on one eye area and a plain hyaluronic acid patch on the other, overnight, over 28 days 5. The active patch did better on eye wrinkles, skin water loss and elasticity, with no adverse effects reported. Several authors worked for the patch maker.
Neither study can tell you what SNAP-8 did on its own, because it was never tested alone.
Does it even reach the muscle?
This is the biggest open question. Expression lines come from muscles that sit beneath the dermis, and peptides like these are large, water-loving molecules that don't cross skin easily.
An FDA lab study tested a cream with 10% argireline on human and guinea pig skin 6. Most of the peptide washed off the surface. About 0.01% of the applied dose reached the epidermis, and none was detected in the dermis or below 6.
Researchers have tried chemically modifying argireline to push it through skin better, which itself shows how poor penetration is 7. SNAP-8 is larger than argireline, so there is no reason to expect it to do better. That is also why the newer studies use microneedles to push it past the outer layer.
Safety and regulatory status
SNAP-8 is a cosmetic ingredient. Cosmetics are not FDA-approved, and no injectable SNAP-8 product is approved. It is a permitted cosmetic ingredient in the EU and UK, and it is not on the WADA prohibited list.
All the human data is from creams, serums or patches. Injecting it is an untested use with unknown safety. The skin studies reported few problems, but mild irritation or redness and rare allergic reactions are possible.
The bottom line
SNAP-8 rests on a plausible lab mechanism borrowed from argireline, which has one small placebo-controlled trial behind it. For SNAP-8 itself, the headline numbers come from its maker, and the only peer-reviewed human studies mixed it with other ingredients in microneedle patches. Expect subtle results at best, and nothing close to botulinum toxin.
This is educational information, not medical advice.
Sources
- A synthetic hexapeptide (Argireline) with antiwrinkle activity — International Journal of Cosmetic Science, Oct 2002. https://pubmed.ncbi.nlm.nih.gov/18498523/
- The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — American Journal of Clinical Dermatology, Apr 2013. https://pubmed.ncbi.nlm.nih.gov/23417317/
- SNAP-8 peptide: an octapeptide to express yourself at ease — Personal Care Magazine (trade feature reporting manufacturer data), Jan 2016. https://www.personalcaremagazine.com/story/15385/
- Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study — Journal of Cosmetic Dermatology, Feb 2020. https://pubmed.ncbi.nlm.nih.gov/31134751/
- Clinical safety and efficacy evaluation of a dissolving microneedle patch having dual anti-wrinkle effects with safe and long-term activities — Annals of Dermatology, Aug 2024. https://pubmed.ncbi.nlm.nih.gov/39082657/
- In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — Cutaneous and Ocular Toxicology, Mar 2015. https://pubmed.ncbi.nlm.nih.gov/24754410/
- Enhanced skin permeation of anti-wrinkle peptides via molecular modification — Scientific Reports, Jan 2018. https://pubmed.ncbi.nlm.nih.gov/29371611/
